Introducing Charles River's latest offering: Off-the-Shelf Rep/Cap Plasmids for AAV Vector Manufacturing
Charles River offers ready-to-use rep/cap plasmids that aim to streamline gene therapy supply chains.
During Advanced Therapies Week, held Jan. 16–19, 2024 in Miami Beach, Fla., Charles River Laboratories International unveiled its new off-the-shelf replication/capsid (rep/cap) plasmids. These plasmids are designed to simplify the manufacturing process of adeno-associated virus (AAV) vectors. The company press release highlights how these plasmids can simplify AAV-based gene therapy programs.
The company has recently introduced AAV rep/cap (RC2, 5, 6, 8, 9) as a complement to their existing lentiviral packaging and AAV helper plasmid products. Charles River states that the plasmid products are manufactured and released based on batch production records. The products provide comprehensive guidance and a certificate of analysis to assist with the filing of investigational new drug and clinical trial applications.
According to the press release, gene therapy developers can benefit from the immediate availability of standard off-the-shelf plasmids, including helper and rep/cap plasmids for AAV production. This can help lower development costs, risks, and timelines. Charles River's rep/cap plasmids have been successfully utilized to facilitate the production of AAV serotypes carrying a wide range of therapeutic transgenes at various stages of development and in compliance with good manufacturing practices.
According to Kerstin Dolph, senior vice-president of Manufacturing at Charles River, the improved efficiency of the supply chain and reduction in production time will greatly contribute to the timely delivery of safe and effective therapies to patients.
